NextCure, Inc. (NXTC)

NextCure's stock price has fluctuated significantly over the past six months. In November 2025, a private placement aimed to raise $21.5 million, extending the company's cash runway into the first half of 2027, led to a 15% increase in share price. The company's Q3 2025 financial results and business update highlighted progress in ADC programs. The Q4 2025 financial results reported a net loss of $55.8 million for 2025, and the company expected financial resources to fund operations into the first half of 2027, which led to a 2.90% stock decline. A January 2026 business update provided updates on SIM0505 and LNCB74. The FDA granted Fast Track designation to SIM0505 for platinum-resistant ovarian cancer.

NextCure, Inc. does not experience traditional demand seasonality as a clinical-stage biopharmaceutical company. The demand for its offerings is driven by unmet medical needs and the scientific and clinical success of its pipeline.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines for cancer and immune-related diseases, targeting patients who do not respond to current therapies or have inadequately addressed cancer types. The company utilizes its FIND-IO™ technology to identify novel targets and is developing product candidates such as SIM0505 (CDH6 ADC), LNCB74 (B7-H4 ADC), NC410, NC525, NC181, and NC605.

NextCure, Inc. is headquartered in Beltsville, Maryland, United States. Clinical testing for SIM0505 is ongoing in the U.S. and China, with plans to expand to Canada and Europe in the second half of 2026 and further study site additions in 2027.

There have been no significant negative events impacting NextCure, Inc.'s brand reputation in the past year. News and updates have primarily focused on clinical trial progress, financial results, and strategic partnerships.

NextCure, Inc. has 27 institutional owners and shareholders holding a total of 1,897,561 shares, including Affinity Asset Advisors, LLC, Ikarian Capital, LLC, and Vanguard Group Inc. Chau Quang Khuong is the largest individual shareholder, owning 2.71 million shares, representing 76.14% of the company.